Popular Articles

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Boston Scientific Corporation (NYSE: BSX) announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The TAXUS Element Stent features a new platinum chromium alloy engineered specifically for coronary stent applications and represents the Company"s third-generation drug-eluting stent (DES) technology.
generic viagra online
Innovative Treatment Approach Offers New Hope For Eczema Sufferers With Moderate To Severe Disease PROTOPIC Ointment Can Help Prevent Eczema Flares
Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flare-free intervals. PROTOPIC ointment (tacrolimus monohydrate) is already licensed to treat moderate and severe eczema (atopic dermatitis), often involving the treatment of flares as and when they occur.* It is now also approved for twice-weekly application to previously affected skin to prevent these exacerbations and prolong flare-free periods in PROTOPIC-responsive patients.ò€  Clinical studies have shown that this new approach brings significant benefits with over 40% of patients with moderate to severe eczema remaining flare-free for at least a year.1 Flares are known to place an enormous burden on patients. The International Study of Life with Atopic Eczema (ISOLATE) found that about 55% of these patients worried about the onset of their next exacerbation and that they spent on average over a third of the year (136 days) with their eczema in flare.2
News of the day
Risk Of Liver Cancer In Women With Hepatitis B Virus Infection Varies With Number Of Pregnancies
Risk for hepatocellular carcinoma, a primary malignancy of the liver, was statistically significantly higher among women with hepatitis B virus (HBV) infection than among women without the virus, according to a study published online June 17 in the JNCI.
Mental Health

Six Words More Than Enough For Senate Battle

"Democrats and Republicans locked horns Friday over inclusion of medical comparative effectiveness study language in a draft health care overhaul measure, suggesting that majority plans to spend only eight days debating and amending the bill may be ambitious," CQ Politics reports. The head-to-head comparisons of medical treatments show how easily a seemingly small provision can become embroiled in major controversy, and demonstrate the potential for indefinite debate. Republicans raise the flag of rationing, saying comparative effectiveness research shouldn"t be used to deny care, while Democrats say they basically agree, but insist on looser language. The current legislative language at the center of the battle? The research "shall not be construed as mandates" (6/19). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):